Denali Therapeutics News Releases http://investors.denalitherapeutics.com/ Denali Therapeutics News Releases en Denali Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designation for DNL310, and Expands its Portfolio of Brain Penetrant Enzyme Replacement Programs http://investors.denalitherapeutics.com/news-releases/news-release-details/denali-therapeutics-receives-orphan-drug-and-rare-pediatric DNL310 on track to enter Phase 1/2 clinical study in Hunter Syndrome patients in 2020 DNL310 utilizes Denali’s proprietary blood-brain barrier crossing enzyme transport vehicle (“ETV”) technology Two additional ETV-enabled enzyme replacement programs were advanced to pre-clinical testing           Tue, 11 Jun 2019 09:00:00 -0400 Denali Therapeutics News Releases 7211 Denali Therapeutics Reports First Quarter 2019 Financial Results http://investors.denalitherapeutics.com/news-releases/news-release-details/denali-therapeutics-reports-first-quarter-2019-financial-results SOUTH SAN FRANCISCO, Calif. , May 08, 2019 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today reported financial results for the first quarter ended March 31, 2019 . Wed, 08 May 2019 16:30:00 -0400 Denali Therapeutics News Releases 7131 Denali Therapeutics Reports Full Year 2018 Financial Results and Business Highlights http://investors.denalitherapeutics.com/news-releases/news-release-details/denali-therapeutics-reports-full-year-2018-financial-results-and SOUTH SAN FRANCISCO, Calif. , March 12, 2019 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today reported financial results for the fourth quarter and full year ended Tue, 12 Mar 2019 09:00:00 -0400 Denali Therapeutics News Releases 7051 Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL747 for Alzheimer’s Disease http://investors.denalitherapeutics.com/news-releases/news-release-details/denali-therapeutics-announces-first-patient-dosed-phase-1b-1 SOUTH SAN FRANCISCO, Calif. , Feb. 15, 2019 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of therapeutic candidates for neurodegenerative diseases, today announced initiation of dosing in a Phase 1b clinical study of DNL747 in Fri, 15 Feb 2019 09:00:00 -0500 Denali Therapeutics News Releases 7031 Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL747 for ALS http://investors.denalitherapeutics.com/news-releases/news-release-details/denali-therapeutics-announces-first-patient-dosed-phase-1b-0 SOUTH SAN FRANCISCO, Calif. , Jan. 08, 2019 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of therapeutic candidates for neurodegenerative diseases, today announced initiation of dosing in a Phase 1b clinical study of DNL747 in Tue, 08 Jan 2019 09:00:00 -0500 Denali Therapeutics News Releases 6971 Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL201 for Parkinson’s Disease http://investors.denalitherapeutics.com/news-releases/news-release-details/denali-therapeutics-announces-first-patient-dosed-phase-1b-study Phase 1b study includes Parkinson’s disease patients with and without a genetic LRRK2 mutation SOUTH SAN FRANCISCO, Calif. , Dec. 10, 2018 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for Mon, 10 Dec 2018 09:00:00 -0500 Denali Therapeutics News Releases 6941 Denali Therapeutics Announces Positive Clinical Results With Its Lead RIPK1 Inhibitor Molecule and Intention to Initiate Patient Studies in Multiple Indications in Collaboration With Sanofi http://investors.denalitherapeutics.com/news-releases/news-release-details/denali-therapeutics-announces-positive-clinical-results-its-lead Phase 1 healthy volunteer study of DNL747 meets all endpoints, including CSF exposure levels, RIPK1 inhibition, and pathway engagement, at doses that were safe and well tolerated Data from the Phase 1 healthy volunteer study of DNL747 will be presented at Denali’s upcoming R&D Day on December 10, Mon, 19 Nov 2018 16:30:00 -0500 Denali Therapeutics News Releases 6901 Denali Therapeutics Reports Third Quarter 2018 Financial Results and Business Highlights and Announces the Appointment of Jennifer Cook to Board of Directors http://investors.denalitherapeutics.com/news-releases/news-release-details/denali-therapeutics-reports-third-quarter-2018-financial-results SOUTH SAN FRANCISCO , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today reported financial results for the third quarter ended September 30, 2018 , provided Thu, 08 Nov 2018 16:30:00 -0500 Denali Therapeutics News Releases 6861 Denali Therapeutics Announces Broad Collaboration with Sanofi to Develop RIPK1 Inhibitors for the Treatment of Neurological and Inflammatory Diseases http://investors.denalitherapeutics.com/news-releases/news-release-details/denali-therapeutics-announces-broad-collaboration-sanofi-develop Candidate RIPK1 inhibitor molecules have the potential to treat Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and systemic inflammatory diseases Denali to receive $125 million upfront payment and future milestone payments that could exceed $1 billion Denali and Thu, 01 Nov 2018 02:00:00 -0400 Denali Therapeutics News Releases 6846 CENTOGENE and Denali Therapeutics Announce Strategic Collaboration to Recruit LRRK2 Patients for Clinical Trials http://investors.denalitherapeutics.com/news-releases/news-release-details/centogene-and-denali-therapeutics-announce-strategic CENTOGENE to conduct a targeted global identification and recruitment campaign to support Denali´s LRRK2 inhibitor program ROSTOCK, Germany & SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 3, 2018-- CENTOGENE and Denali Therapeutics (NASDAQ: DNLI) today announced a strategic collaboration for Wed, 03 Oct 2018 09:00:00 -0400 Denali Therapeutics News Releases 6816